1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Regulatory Briefs: U.K. Trials Database; Hospitals Seek UDI Rule; FDA Workshops

The U.K.’s National Health Service is requiring all U.K. trials to be registered in a clinical trial database. Five influential hospital systems urge the White House to release the UDI final rule. FDA schedules metabolic disease workshop. More regulatory news.

The Health Research Authority, an arm of the U.K.’s National Health Service, is implementing plans to make registration in a publicly accessible clinical trial database a condition of gaining approval from an ethics committee starting Sept. 30. In a Sept. 11 announcement, Janet Wisely, chief executive of HRA, said, “We are fully committed to the principles of transparency in health research. Including a requirement for registration as a condition of the favorable ethical opinion is a significant step towards this.” Failure to register will be a breach of good research practice. The mandated trial registration will initially apply to clinical trials of medical devices and investigational medicinal products. HRA expects all studies to be registered when the first patient is recruited, and will be considered breached if trials aren’t registered within six weeks of patient enrollment. The group expects current and previous studies as well as future studies to be registered in the database.

The Healthcare Transformation Group, composed of five health care systems, sent a letter Sept. 6 to the White...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Regulation

Burden Is Too Heavy For Medtechs To Go It Alone On Complex Medtech AI Projects

 
• By Amanda Maxwell

Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

 
• By Elizabeth Orr

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 
• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

More from Policy & Regulation

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 
• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By Marion Webb

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 
• By Malcolm Spicer

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.